Search research articles
Contact Us
Filters
Showing results (71-80 of 92) with videos related to
Page
of 10
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
June 20, 2020
Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
January 28, 2021
Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.
Journal of Gastroenterology
|
December 8, 2004
Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response
Yasuharu Imai, Akinori Kasahara, Hideo Tanaka, et al.
Hepatology Communications
|
August 11, 2018
Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C
Yuki Tahata, Ryotaro Sakamori, Ayako Urabe, et al.
Journal of Gastroenterology
|
May 9, 2014
The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1
Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Journal of Gastroenterology
|
October 19, 2006
Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C
Tsugiko Oze, Naoki Hiramatsu, Nao Kurashige, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
November 24, 2007
Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine
Nao Kurashige, Naoki Hiramatsu, Kazuyoshi Ohkawa, et al.
Alimentary Pharmacology & Therapeutics
|
October 7, 2021
Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals
Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, et al.
Journal of Gastroenterology
|
August 23, 2011
Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study
Naoki Hiramatsu, Yuko Inoue, Tsugiko Oze, et al.
Scientific Reports
|
January 31, 2017
Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment
Yugo Kai, Hayato Hikita, Naoki Morishita, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 92) with videos related to
Sort By:
Page
of 10
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
June 20, 2020
Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
January 28, 2021
Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.
Journal of Gastroenterology
|
December 8, 2004
Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response
Yasuharu Imai, Akinori Kasahara, Hideo Tanaka, et al.
Hepatology Communications
|
August 11, 2018
Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C
Yuki Tahata, Ryotaro Sakamori, Ayako Urabe, et al.
Journal of Gastroenterology
|
May 9, 2014
The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1
Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Journal of Gastroenterology
|
October 19, 2006
Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C
Tsugiko Oze, Naoki Hiramatsu, Nao Kurashige, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
November 24, 2007
Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine
Nao Kurashige, Naoki Hiramatsu, Kazuyoshi Ohkawa, et al.
Alimentary Pharmacology & Therapeutics
|
October 7, 2021
Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals
Yuki Tahata, Ryotaro Sakamori, Ryoko Yamada, et al.
Journal of Gastroenterology
|
August 23, 2011
Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study
Naoki Hiramatsu, Yuko Inoue, Tsugiko Oze, et al.
Scientific Reports
|
January 31, 2017
Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment
Yugo Kai, Hayato Hikita, Naoki Morishita, et al.
Page
of 10